Hojjat Eghbali Jelodar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hojjat Eghbali Jelodar has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Mobin Forghan
Department of Surgery and Orthopedic, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
2 shared publications - A. Alilou
Department of Surgery and Orthopedic, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
1 shared publication Abnoos Mokhtariardekani
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Science & Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication- Amin Norouzbeygi
Department of Orthopedic and Trauma Surgery, School of Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
1 shared publication - Asaad Abass Fadhel Khalif
Department of Pharmacology and Toxicology, Al-Mustansiriyah University, College of Pharmacy, Baghdad, Iraq
1 shared publication - Hanie Fooladi
Department of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication
Latest Publications
- 1 January 2026
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 14 (1) , e13322
Molecular pathways shaping bone function following SGLT2 inhibitor therapy; a narrative insight from metabolic and endocrine crosstalk
A sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy promotes renal glucosuria, which triggers phosphaturia and initiates a cascade of metabolic and hormonal disturbances. The resulting hypophosphatemia stimulates secondary hyperparathyroidism, which in turn elevates fibroblast growth factor 23 (FGF23), further suppressing serum phosphate, calcitriol, and calcium levels. Concurrently, the osmotic diuresis and caloric loss induce a negative energy balance, shifting metabolism toward ketogenesis. Elevated β-hydroxybutyrate not only serves as an alternative fuel but also directly stimulates osteoclast activity while inhibiting osteoblast function. Compounding this, therapy-associated hypoinsulinemia diminishes anabolic signaling through insulin and insulin-like growth factor-1 (IGF-1), both critical for bone formation. At the heart of this skeletal disruption lies osteocyte dysfunction. Hypophosphatemia and altered hormonal milieu—particularly increased PTH and FGF23 upregulate sclerostin, a potent inhibitor of the Wnt/β-catenin pathway, thereby suppressing bone formation. Furthermore, alterations in adipokines following weight loss further modulate bone metabolism. Critically, these pathways interact synergistically: PTH enhances bone resorption and sclerostin production; FGF23 suppresses calcitriol, worsening hypocalcemia; and ketones amplify RANKL-driven osteoclastogenesis. Additionally, mechanical unloading from rapid weight loss independently increases sclerostin expression. The net effect is a profound uncoupling of bone remodeling, accelerated resorption driven by PTH, RANKL, ketones, and inflammatory cytokines, coupled with suppressed formation due to sclerostin, hypoinsulinemia, and direct ketone effects. Clinically, this manifests as rapid trabecular bone loss, deteriorated microarchitecture, and a markedly elevated fracture risk, particularly during the initial months of treatment. Therefore, SGLT2 inhibitors confer significant cardio-renal benefits; however, they may impose substantial skeletal trade-offs that warrant careful monitoring.
- 1 January 2026
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 14 (1) , e13322
Molecular pathways shaping bone function following SGLT2 inhibitor therapy; a narrative insight from metabolic and endocrine crosstalk
A sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy promotes renal glucosuria, which triggers phosphaturia and initiates a cascade of metabolic and hormonal disturbances. The resulting hypophosphatemia stimulates secondary hyperparathyroidism, which in turn elevates fibroblast growth factor 23 (FGF23), further suppressing serum phosphate, calcitriol, and calcium levels. Concurrently, the osmotic diuresis and caloric loss induce a negative energy balance, shifting metabolism toward ketogenesis. Elevated β-hydroxybutyrate not only serves as an alternative fuel but also directly stimulates osteoclast activity while inhibiting osteoblast function. Compounding this, therapy-associated hypoinsulinemia diminishes anabolic signaling through insulin and insulin-like growth factor-1 (IGF-1), both critical for bone formation. At the heart of this skeletal disruption lies osteocyte dysfunction. Hypophosphatemia and altered hormonal milieu—particularly increased PTH and FGF23 upregulate sclerostin, a potent inhibitor of the Wnt/β-catenin pathway, thereby suppressing bone formation. Furthermore, alterations in adipokines following weight loss further modulate bone metabolism. Critically, these pathways interact synergistically: PTH enhances bone resorption and sclerostin production; FGF23 suppresses calcitriol, worsening hypocalcemia; and ketones amplify RANKL-driven osteoclastogenesis. Additionally, mechanical unloading from rapid weight loss independently increases sclerostin expression. The net effect is a profound uncoupling of bone remodeling, accelerated resorption driven by PTH, RANKL, ketones, and inflammatory cytokines, coupled with suppressed formation due to sclerostin, hypoinsulinemia, and direct ketone effects. Clinically, this manifests as rapid trabecular bone loss, deteriorated microarchitecture, and a markedly elevated fracture risk, particularly during the initial months of treatment. Therefore, SGLT2 inhibitors confer significant cardio-renal benefits; however, they may impose substantial skeletal trade-offs that warrant careful monitoring.
- 10 December 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
When tumors break bones; emerging paradigms in the pathogenesis and prevention of oncologic skeletal fractures
Oncologic skeletal fractures or pathologic fractures resulting from tumor-induced bone destruction represent a devastating complication of both primary bone cancers and metastatic disease, profoundly impairing patient quality of life and survival. Traditionally viewed as mechanical failures secondary to osteolytic or osteoblastic lesions, emerging paradigms now recognize these fractures as the culmination of complex, dynamic interactions between tumor cells and the bone microenvironment. Recent advances highlight the role of tumorsecreted factors, which dysregulate normal bone remodeling by takeover of osteoclast and osteoblast activity, leading to structural weakening long before radiographic changes appear. Moreover, the concept of the vicious cycle between tumor growth and bone resorption has been expanded to include immune modulation, angiogenesis, and neural signaling within the skeletal niche. Novel imaging modalities and biomechanical modeling now enable earlier detection of at-risk bone, while biomarkers offer promise for risk stratification. Therapeutically, beyond bisphosphonates and denosumab, emerging strategies target specific molecular pathways like TGF-β, Wnt, CXCR4 to disrupt tumor-bone crosstalk and preserve skeletal integrity. Additionally, prophylactic stabilization guided by fracture risk assessment tools is increasingly personalized. Meanwhile, prevention, rather than reaction, is becoming the cornerstone of management, emphasizing collaboration among oncologists, orthopedic surgeons, radiologists, and bone biologists.
- 10 December 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
When tumors break bones; emerging paradigms in the pathogenesis and prevention of oncologic skeletal fractures
Oncologic skeletal fractures or pathologic fractures resulting from tumor-induced bone destruction represent a devastating complication of both primary bone cancers and metastatic disease, profoundly impairing patient quality of life and survival. Traditionally viewed as mechanical failures secondary to osteolytic or osteoblastic lesions, emerging paradigms now recognize these fractures as the culmination of complex, dynamic interactions between tumor cells and the bone microenvironment. Recent advances highlight the role of tumorsecreted factors, which dysregulate normal bone remodeling by takeover of osteoclast and osteoblast activity, leading to structural weakening long before radiographic changes appear. Moreover, the concept of the vicious cycle between tumor growth and bone resorption has been expanded to include immune modulation, angiogenesis, and neural signaling within the skeletal niche. Novel imaging modalities and biomechanical modeling now enable earlier detection of at-risk bone, while biomarkers offer promise for risk stratification. Therapeutically, beyond bisphosphonates and denosumab, emerging strategies target specific molecular pathways like TGF-β, Wnt, CXCR4 to disrupt tumor-bone crosstalk and preserve skeletal integrity. Additionally, prophylactic stabilization guided by fracture risk assessment tools is increasingly personalized. Meanwhile, prevention, rather than reaction, is becoming the cornerstone of management, emphasizing collaboration among oncologists, orthopedic surgeons, radiologists, and bone biologists.
- Open Access
- 3 September 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13, e13302
Inflammatory impact of cigarette smoking on bone function and structure; a review of evidence
Cigarette smoking represents a major lifestyle risk factor for bone loss and skeletal disorders, with complex etiological mechanisms consisting both direct tissue effects and systemic alterations. Recent evidence demonstrates that tobacco smoking triggers an intricate cascade of cellular and molecular events that disrupts the delicate balance of bone remodeling, finally leading to decreased bone mass and increased fracture risk.
- 3 September 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13, e13302
Open AccessInflammatory impact of cigarette smoking on bone function and structure; a review of evidence
Cigarette smoking represents a major lifestyle risk factor for bone loss and skeletal disorders, with complex etiological mechanisms consisting both direct tissue effects and systemic alterations. Recent evidence demonstrates that tobacco smoking triggers an intricate cascade of cellular and molecular events that disrupts the delicate balance of bone remodeling, finally leading to decreased bone mass and increased fracture risk.